tert-butyl 4-(cyclopentyloxy)benzylcarbamate | 1241911-15-8

• 英文名称: tert-butyl 4-(cyclopentyloxy)benzylcarbamate
• 英文别名: Tert-butyl N-{[4-(cyclopentyloxy)phenyl]methyl}carbamate；tert-butyl N-[(4-cyclopentyloxyphenyl)methyl]carbamate
• CAS: 1241911-15-8
• 化学式: C₁₇H₂₅NO₃
• mdl: MFCD24393281
• 分子量: 291.39
• InChiKey: IKZMOEKOIYJKKL-UHFFFAOYSA-N

物化性质

• 沸点：
  429.3±28.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.588
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(cyclopentyloxy)benzylcarbamate 在 三氟乙酸 、 lithium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 73.5h， 生成 3-(2-(tert-butylamino)-1-(N-(4-(cyclopentyloxy)benzyl)formamido)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

  摘要：

  Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient alpha-helical N-terminal "lid" segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111588
• 作为产物：
  描述：

  环戊醇 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 20.0~70.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 生成 tert-butyl 4-(cyclopentyloxy)benzylcarbamate
  参考文献：
  名称：

  [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  [FR] COMPOSÉS PYRROLINONE CARBOXAMIDE UTILES COMME INHIBITEURS DE LIPASE ENDOTHÉLIALE

  摘要：

  本发明提供了以下式（I）的化合物：（I），如规范中定义的，并包括任何此类新化合物的组合物。这些化合物是内皮酶抑制剂，可用作药物。

  公开号：

  WO2013048928A1

文献信息

• NOVEL BRONCHODILATING DIAZAHETEROARYLS
  申请人：Johansson Martin

  公开号：US20120040942A1

  公开（公告）日：2012-02-16

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• [EN] NOVEL BRONCHODILATING DIAZAHETEROARYLS<br/>[FR] NOUVEAUX DIAZAHÉTÉROARYLES BRONCHODILATATEURS
  申请人：RESPIRATORIUS AB

  公开号：WO2010097410A1

  公开（公告）日：2010-09-02

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140228321A1

  公开（公告）日：2014-08-14

  The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了公式（I）的化合物：（I），如规范所定义的和包含任何这样的新化合物的组合物。这些化合物是内皮细胞脂肪酶抑制剂，可用作药物。
• NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY
  申请人：Respiratorius AB

  公开号：EP2401275B1

  公开（公告）日：2013-07-24
• US8415333B2
  申请人：——

  公开号：US8415333B2

  公开（公告）日：2013-04-09